Kathy Giusti, M.B.A. ’85, founder and CEO of the Multiple Myeloma Research Foundation (MMRF), will address this year's imminent graduates of Harvard Business School as Class Day speaker. She founded the MMRF in 1998 after being diagnosed with multiple myeloma. This spring, Time magazine named her one of the "100 most influential people" in the world. Multiple myeloma is a cancer of plasma cells—white blood cells that produce antibodies; it affects from one to four people per 100,000 and constitutes 1 percent of all cancers. Before starting MMRF, Giusti was an executive with pharmaceutical companies, and she has sought to encourage the development of drugs to treat the disease using a business model, rather than an academic model, of drug development. The MMRF is the world's top funder of myeloma research: it has raised more than $165 million to fund research.
Multiple myeloma research crusader Kathy Giusti to speak at HBS Class Day
The founder of the Multiple Myeloma Research Foundation will speak at Harvard Business School Class Day.
Kathy Giusti | Photograph courtesy of the Multiple Myeloma Research Foundation
You might also like
Graduate Student Union Schedules Strike
The work stoppage will begin October 27, unless a final bargaining session next week yields an agreement.
Harvard Stabilizes Finances With Strong Endowment Returns, Philanthropy
Small operating surplus is dwarfed by reduced federal research support and endowment tax liabilities.
Harvard Graduate Student Union Authorizes Another Strike
The University warns this walkout may not be protected by labor law, an assertion the union disputes.
Most popular
Explore More From Current Issue
Why Harvard Medical School is training physicians to think more like coaches
Your thoughts on how to regulate the platforms—and stop using them so much
The University is expanding industry ties and investing its own funds to support research, but neither will replace lost federal dollars.